Molecular Testing
-
October 16, 2020
Molecular Profiling in Metastatic Colorectal CancerBookmark
George Lundberg, MDArticle from the academic journal Oncology, curated by Contributing Editor George Lundberg, MD, who notes:
Molecular testing is essential to guide effective treatment in metastatic colorectal cancer. This academic review article provides a good overview of the topic.
.
-
August 21, 2020
The Power of Precision Medicine is Exemplified by Tempus
With:Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.
-
August 18, 2020
Tumor Boards—What Are They and How Can They Help You?
One of the most powerful tools in cancer treatment today is the tumor board—a group of cancer experts who delve into individual cancer patients’ cases to help them explore their… Read more »
-
August 15, 2020
Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted TherapyBookmark
George Lundberg, MDArticle from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
The Central Nervous System Tumor Methylation Classifier Changes Neuro-Oncology Practice for Challenging Brain Tumor Diagnoses and Directly Impacts Patient CareBookmark
George Lundberg, MDAcademic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes:
Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.
Go to full academic research paper from Clinical Epigenetics.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 12, 2020
Pancreatic Cancer Survival Rates: What Do They Really Mean?
Lola Rahib, PhDThe American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic… Read more »
-
April 27, 2020
The Challenges of Using Artificial Intelligence to Improve Cancer Treatment
With: Razelle Kurzrock, MDJeff Shrager, PhDIn a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile.… Read more »
-
April 9, 2020
Molecularly Guided Therapy in Pancreatic Cancer: Untapped Potential and the ‘Bright Future’ AheadBookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Molecularly matched treatment for pancreatic cancer may extend life for some patients.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
March 2, 2020
Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology
With: Razelle Kurzrock, MDA Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch,… Read more »
-
February 21, 2020
Comprehensive Molecular Testing Needed for Stage IV Lung Cancer
With:A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an… Read more »